20 Years of Gene Therapy for SCID

Overview

Journal Nat Immunol

Date 2010 May 21

PMID 20485269

Citations 49

Authors

Alain Fischer

Salima Hacein-Bey-Abina

Marina Cavazzana-Calvo

Affiliations

Soon will be listed here.

Citing Articles

Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies.

Andreana I, Repellin M, Carton F, Kryza D, Briancon S, Chazaud B Pharmaceutics. 2021; 13(2).

PMID: 33669654 PMC: 7922331. DOI: 10.3390/pharmaceutics13020278.

HK022 bacteriophage Integrase mediated RMCE as a potential tool for human gene therapy.

Elias A, Kassis H, Elkader S, Gritsenko N, Nahmad A, Shir H Nucleic Acids Res. 2020; 48(22):12804-12816.

PMID: 33270859 PMC: 7736782. DOI: 10.1093/nar/gkaa1140.

Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Brommel C, Cooney A, Sinn P Hum Gene Ther. 2020; 31(17-18):985-995.

PMID: 32718227 PMC: 7495917. DOI: 10.1089/hum.2020.138.

Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.

Garcia-Perez L, van Eggermond M, van Roon L, Vloemans S, Cordes M, Schambach A Mol Ther Methods Clin Dev. 2020; 17:666-682.

PMID: 32322605 PMC: 7163047. DOI: 10.1016/j.omtm.2020.03.016.

Gene correction for SCID-X1 in long-term hematopoietic stem cells.

Pavel-Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C Nat Commun. 2019; 10(1):1634.

PMID: 30967552 PMC: 6456568. DOI: 10.1038/s41467-019-09614-y.

References

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

Check E . Second cancer case halts gene-therapy trials. Nature. 2003; 421(6921):305. DOI: 10.1038/421305a. View

Lombardo A, Genovese P, Beausejour C, Colleoni S, Lee Y, Kim K . Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007; 25(11):1298-306. DOI: 10.1038/nbt1353. View

Howe S, Mansour M, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H . Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118(9):3143-50. PMC: 2496964. DOI: 10.1172/JCI35798. View

Cartier N, Hacein-Bey-Abina S, Bartholomae C, Veres G, Schmidt M, Kutschera I . Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326(5954):818-23. DOI: 10.1126/science.1171242. View

Check E . NIH open-access plans draw fire from both sides. Nature. 2005; 433(7026):561. DOI: 10.1038/433561b. View

Check E . Gene therapists hopeful as trials resume with childhood disease. Nature. 2004; 429(6992):587. DOI: 10.1038/429587a. View

Check E . Gene therapy: shining hopes dented - but not dashed. Nature. 2002; 420(6917):735. DOI: 10.1038/420735b. View

10.

Check E . Cancer risk prompts US to curb gene therapy. Nature. 2003; 422(6927):7. DOI: 10.1038/422007a. View

11.

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

12.

Check E . A tragic setback. Nature. 2002; 420(6912):116-8. DOI: 10.1038/420116a. View

13.

Check E . Harmful potential of viral vectors fuels doubts over gene therapy. Nature. 2003; 423(6940):573-4. DOI: 10.1038/423573a. View

14.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack M, Wulffraat N, Leboulch P . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644):415-9. DOI: 10.1126/science.1088547. View

15.

Check E . Cancer fears cast doubts on future of gene therapy. Nature. 2003; 421(6924):678. DOI: 10.1038/421678b. View

16.

Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, de Villartay J . Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002; 346(16):1185-93. DOI: 10.1056/NEJMoa012616. View

17.

Gaspar H, Parsley K, Howe S, King D, Gilmour K, Sinclair J . Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004; 364(9452):2181-7. DOI: 10.1016/S0140-6736(04)17590-9. View

18.

Kohn D, Hershfield M, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska E . T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998; 4(7):775-80. PMC: 3777239. DOI: 10.1038/nm0798-775. View

19.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A . Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296(5577):2410-3. DOI: 10.1126/science.1070104. View

20.

Gatti R, Meuwissen H, ALLEN H, Hong R, GOOD R . Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968; 2(7583):1366-9. DOI: 10.1016/s0140-6736(68)92673-1. View